122 related articles for article (PubMed ID: 16503937)
1. [New therapeutic approaches for solid tumors: histone deacetylase, methyltransferase and proteasome inhibitors].
Becker JC; Ugurel S; Bröcker EB; Schrama D; Houben R
J Dtsch Dermatol Ges; 2006 Feb; 4(2):108-13. PubMed ID: 16503937
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted therapy for melanoma: current reality and future options.
Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
4. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
5. [Kinase inhibitors for the therapy of malignant melanoma].
Becker JC; Schrama D; Bröcker EB; Houben R
J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic tools in potential anticancer therapy.
Sebova K; Fridrichova I
Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
9. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis.
Vogiatzi P; Vindigni C; Roviello F; Renieri A; Giordano A
J Cell Physiol; 2007 May; 211(2):287-95. PubMed ID: 17238139
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
[TBL] [Abstract][Full Text] [Related]
14. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
16. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
17. Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy.
Snykers S; Vinken M; Rogiers V; Vanhaecke T
Arch Toxicol; 2007 Aug; 81(8):533-44. PubMed ID: 17387455
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic biomarkers for human cancer: the time is now.
Mulero-Navarro S; Esteller M
Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
[TBL] [Abstract][Full Text] [Related]
19. Cancer treatment of the future: inhibitors of histone methyltransferases.
Spannhoff A; Sippl W; Jung M
Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]